Silo Pharma rises on pre-clinical data on novel Alzheimer's drug

Silo Pharma

20/10/2022 14:39

** Silo Pharma Inc's shares  SILO.O  up 5.9% at $5.06 
    ** SILO announces proof-of-concept data supporting the
therapeutic potential of its drug "SPC-14" as a treatment for
Alzheimer's disease
    ** SPC-14, a novel drug that combines an FDA-approved
therapeutic with ketamine, is in development for the treatment
of dementia related to Alzheimer's disease
    ** Up to Wednesday's close, stock had fallen 32.9% YTD 
 (Reporting by Sourasis Bose in Bengaluru)
 ((Sourasis.bose@thomsonreuters.com))